Publications by authors named "Anthony Jaworski"
Article Synopsis
- Regorafenib, an oral multikinase inhibitor, was tested in the INTEGRATE IIa trial to see if it improves overall survival in patients with advanced gastric and esophagogastric junction cancer who did not respond to at least two prior treatments.
- The trial compared regorafenib plus supportive care against a placebo with supportive care, enrolling 251 participants and evaluating various outcomes like overall survival (OS), progression-free survival (PFS), and quality of life (QoL).
- Results showed that regorafenib significantly improved OS and PFS compared to placebo, with a median OS of 4.5 months for those receiving regorafenib versus 4.0 months for those on placebo, while also
Background: Advanced gastro-oesophageal cancer (AGOC) carries a poor prognosis. No standard of care treatment options are available after first and second-line therapies. Regorafenib is an oral multi-targeted tyrosine kinase inhibitor targeting angiogenic, stromal, and oncogenic receptor tyrosine kinases.
View Article and Find Full Text PDFObjectives: To assess the evidence and discuss the risks and clinical relevance of ketamine for the treatment of various disease states impacting the adult critically ill population.
Data Sources: A literature review was performed using PubMed evaluating primary literature published until August 2018.
Study Selection: Case reports, observational studies (cohort, case-control), and randomized controlled trials involving patients 18 years and older in a nonperioperative setting using either IV or intramuscular ketamine were included for analysis.
The popularity of recreational synthetic drug use has increased within the past several years. Emergency physicians, along with prehospital providers, are often the first to interact with patients who use these new drugs. We report the case of a 27-year-old male with two emergency department visits with confirmed ingestion of a relatively new synthetic drug of abuse.
View Article and Find Full Text PDFIntroduction: Little is known regarding age-related risk of nephrotoxicity during vancomycin therapy after the publication of the 2009 vancomycin consensus guidelines for therapeutic drug monitoring. We sought to evaluate incidence and risk factors for acute kidney injury in three age groups.
Methods: Matched cohort study of patients receiving vancomycin, grouped by age: young adults (18-64 years), older adults (65-79 years) and very elderly (≥80 years), matched on previously published risk factors for nephrotoxicity.